查詢結果分析
相關文獻
- Clinical Experience of Oral Treatment with Desmopressin in Central Diabetes Insipidus
- 尿液化學之臨床應用
- 兼論中樞性尿崩症影像診斷之進展
- 中樞性尿崩症的治療及病例討論
- Efficacy and Dose Adjustment of Oral Desmopressin (DDAVP) in Patients with Central Diabetes Insipidus
- 血清滲透壓值的應用與限制
- 中樞性尿崩症合併非阻塞性泌尿道擴張及不明原因之低血鉀症:病例報告
- 中樞性尿崩症之案例報告
- Al Diabetes Insipidus and Langerhans Cell Stiocytosis--A Case Report and Review of Literature
- 治療中樞性尿崩症使用Desmopressin中同時發生深部靜脈血栓與肺動脈血栓:病例報告
頁籤選單縮合
題 名 | Clinical Experience of Oral Treatment with Desmopressin in Central Diabetes Insipidus=口服desmopressin在中樞性尿崩症之治療經驗 |
---|---|
作 者 | 張天鈞; 蔡克嵩; 蕭永廉; 林瑞明; | 書刊名 | 慈濟醫學 |
卷 期 | 9:3 1997.09[民86.09] |
頁 次 | 頁183-190 |
分類號 | 418.223 |
關鍵詞 | 中樞性尿崩症; 口服desmopressin; 尿液滲透壓; 血清滲透壓; Central diabetes insipidus; Oral desmopressin; Urine osmolality; Serum osmolality; |
語 文 | 英文(English) |
中文摘要 | 為瞭解口服desmopressin(DDAVP)對罹患中樞性尿崩症的治療效果,本研究對8位過去 使用經鼻腔給予DDAVP的病人,於停藥一天後,第一天測定基礎值24小時尿量及尿滲透壓,第二 至第四天各做口服DDAVP100μg、200μg及400μg之劑量滴定試驗,觀察尿量和尿滲透壓變化。出 院後根據劑量滴定試驗結果給藥。病人每星期回門診一次,共四次,回診前一日,記載24小時尿量, 並測其滲透壓。結果顯示病人在治療前之基礎值尿量為8770±4026mL(平均值±標準差),尿液滲 透壓為153.9±78.2mOsm/Kg。在劑量滴定試驗方面,口服DDAVP後2至4小時間,其降低尿量作 用最明顯,隨後有反彈之現象,然後再恢復到基礎值。尿液滲透壓則於2至4小時達到最高點。出 院後,24小時尿量在第四星期時降為2513±1355mL,尿液滲透壓上升為429.8±143.3mOsm/Kg。 DDAVP劑量,試驗前經鼻腔給予時為每日12.5μg(中數),範圍為8 -50μg。口服時每日300μg(中 數),範圍為200-2100μg。兩者無統計學上有意義之相關。副作用方面,在觀察期間,一例有暫時 性骨頭酸痛,一例在做400μg試驗時有暫時性腹痛,一例在第一星期時有頭痛、嗜睡的現象。停止 臨床試用後,這8位病人皆認為用口服計型較鼻腔給予劑型方便,希望能繼續使用口服劑型。本研 究顯示口服DDAVP是治療中樞性尿崩症的安全、有效且方便的藥物。 |
英文摘要 | To elucidate the effects of oral desmopressin(DDAVP) on central diabetes insipidus, basal 24 hour-urine and its osmolality were determined in 8 patients after discontinuation of intranasal DDAVP for 24 hrs. Then, 100μg, 200μg, and 400μg of oral DDAVP were given of the 2□, 3□ and 4□ days, respectively, and hourly urine and osmolality were monitored. Patients were treated with optimal doses, and asked to return to the clinic every week for 4 weeds. Twenty-four-hour urine amounts were recorede and their osmolalities were determined during each visit. The results showed that the baseline 24-hour urine amounts averaged 8770±4026mL(mean±SD), and osmolality averaged 153.9±78.2mOsm/Kg. In the dose titration test, urine amounts decreased remarkably agter 2 to 4 hours, followed by a rebound, and then a gradual return to baseline leves. Urine osmolalities increased, peaking after 2 to 4 hours, then gradually returning to the baseline levels. During the follow-up period, daily urine amounts decreased to 2513± 1355mL, and urine osmolalities increased to 429.8±143.3mOsm/Kg by the 4th week. The median intranasal DDAVP dose used daily before the clinical trial was 12.5μg(range 8 to 50μg). The median daily oral DDAVP dose used by the 4th week was 300μg(range 200 to 2100μg).One patient experienced transient arthralgia, one patient experienced transient abdominal pain, and another pa- tient experienced temporary headaches and sleepiness. All the patients asked for continuation of the oral DDAVP treatment instead of a return to the intranasal form. These results suggest that oral DDAVP is safe, effective and convenient for treatment of central diabetes insipidus. |
本系統中英文摘要資訊取自各篇刊載內容。